Tetrahydrohomofolate polyglutamates as inhibitors of thymidylate synthase and glycinamide ribonucleotide formyltransferase in Lactobacillus casei
- PMID: 2106831
- DOI: 10.1016/0003-9861(90)90588-p
Tetrahydrohomofolate polyglutamates as inhibitors of thymidylate synthase and glycinamide ribonucleotide formyltransferase in Lactobacillus casei
Abstract
In order to determine the mechanism for the effects of homofolates on growth of Lactobacillus casei, polyglutamated derivatives of homofolate (HPteGlu), dihydrohomofolate and tetrahydrohomofolate (H4HPteGlu) were synthesized and tested as inhibitors of folate-requiring enzymes. The following L. casei enzymes were examined: thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFT), aminoimidazolecarboxamide ribonucleotide formyltransferase, serine hydroxymethyltransferase and dihydrofolate reductase. Polyglutamates of (6R,S)-H4HPteGlu are potent inhibitors of TS and GARFT. For example, the IC50 values of (6R,S)-H4HPteGlu6 are 0.7 microM for TS and 0.3 microM for GARFT. By contrast, the value for HPteGlu6 is greater than 10 microM for both TS and GARFT. Inhibition of TS and GARFT by (6R,S)-H4HPteGlu derivatives increases with polyglutamate chain length. For TS, the Glu5 and Glu6 derivatives of (6R,S)-H4HPteGlu are 20 and 30 times more potent than the monoglutamate, respectively. For GARFT, the Glu2-6 derivatives are 2-3 times more potent than Glu1. Inhibition of TS and GARFT by (6R,S)-H4HPteGlu polyglutamates is almost entirely due to the unnatural (6R) diastereomer at C-6. Homofolate derivatives are only weak inhibitors of aminoimidazolecarboxamide ribonucleotide formyltransferase, serine hydroxymethyltransferase, and dihydrofolate reductase. We conclude that both TS and GARFT are potential targets of (6R)-H4HPteGlu polyglutamates.
Similar articles
-
Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.Cancer Res. 1989 Jan 1;49(1):158-63. Cancer Res. 1989. PMID: 2521177
-
Folate analogues. 31. Synthesis of the reduced derivatives of 11-deazahomofolic acid, 10-methyl-11-deazahomofolic acid, and their evaluation as inhibitors of glycinamide ribonucleotide formyltransferase.J Med Chem. 1989 Jun;32(6):1277-83. doi: 10.1021/jm00126a022. J Med Chem. 1989. PMID: 2498518
-
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.Cancer Res. 1992 Apr 15;52(8):2148-55. Cancer Res. 1992. PMID: 1313737
-
Inhibitors of thymidylate synthase and glycinamide ribonucleotide transformylase.Adv Exp Med Biol. 1994;370:179-83. doi: 10.1007/978-1-4615-2584-4_39. Adv Exp Med Biol. 1994. PMID: 7660885 Review. No abstract available.
-
Deaza analogs of folic acid as antitumor agents.Curr Pharm Des. 2003;9(31):2615-25. doi: 10.2174/1381612033453695. Curr Pharm Des. 2003. PMID: 14529545 Review.
Cited by
-
Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate.Front Pharmacol. 2022 Oct 4;13:1001308. doi: 10.3389/fphar.2022.1001308. eCollection 2022. Front Pharmacol. 2022. PMID: 36267288 Free PMC article.
-
The effect of inhibiting glycinamide ribonucleotide formyl transferase on the development of neural tube in mice.Nutr Metab (Lond). 2016 Aug 23;13(1):56. doi: 10.1186/s12986-016-0114-x. eCollection 2016. Nutr Metab (Lond). 2016. PMID: 27555878 Free PMC article.
-
A journey into the regulatory secrets of the de novo purine nucleotide biosynthesis.Front Pharmacol. 2024 Feb 20;15:1329011. doi: 10.3389/fphar.2024.1329011. eCollection 2024. Front Pharmacol. 2024. PMID: 38444943 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical